Aligos Therapeutics Q3 net loss narrows on lower R&D costs
ALGS•Aligos Therapeutics reported a third-quarter net loss of $21.86 million, or $2.09 per share, both below analyst estimates. Operating expenses were $24.76 million, and the company said cash and investments are expected to fund operations into the first quarter of 2027.
1. Quarterly results
Aligos Therapeutics reported a third-quarter net loss of $21.86 million, compared with an analyst consensus estimate of $24.74 million. Loss per share was $2.09 versus an expected $2.17, while operating expenses were $24.76 million.
2. Trial costs and cash
The company said operating expenses fell year over year, mainly because of lower third-party costs for the Phase 2 pevifoscorvir sodium trial. Enrollment in the Phase 2 B-SUPREME study is complete. Aligos expects its cash and investments to fund operations into the first quarter of 2027.
